Background The role of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin
receptor blockers (ARBs) reducing risk of cardiovascular events (CVEs) and preserving …

Although angiotensin‐converting enzyme inhibitors are frequently used as antihypertensive
agents to lower blood pressure and slow progression of nephropathy in patients with type 2 …

Background: Diabetic nephropathy (DN) is one of the most typical microangiopathies
caused by diabetes. It often leads enormous physiological and psychological burdens for …

Reducing the actions of the renin-angiotensin-aldosterone system with angiotensin-
converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) …

Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor
blockers (ARBs). A 2011 meta-analysis of 5 RCTs (total 2975 patients) that compared ACE …

In the past few years diabetes has become the leading cause of end-stage renal disease in
all Western countries. A correlation between blood pressure and rate of progression in …

Aims/hypothesis This meta-analysis aimed to compare the renal outcomes between ACE
inhibitor (ACEI)/angiotensin II receptor blocker (ARB) and other antihypertensive drugs or …

Chronic renal disease is characterized by a gradual loss of renal function and an increased
cardiovascular risk. Renin-angiotensin system blockade by angiotensin-converting enzyme …

Renal complications resulting from type 2 diabetes mellitus are costly and common. Finding
optimal therapy is important for the prevention and management of diabetic nephropathy …

Substantial morbidity, mortality, and costs are associated with progressive diabetic kidney
disease (DKD). A goal of H ealthy P eople 2020 is to reduce kidney disease attributable to …